Overview
Medical treatment for people who wish to live as the opposite sex is about a hundred years old. In that time it has passed through several distinct eras, each built on different ideas about who the patients were, what was wrong, and what doctors should do about it:
- The experimental era (1919–1950s). A handful of doctors in Weimar Berlin and, later, Copenhagen tried castration, early hormone preparations and genital surgery on a small number of mostly male patients.
- The clinic era (1960s–1970s). University gender clinics in the United States and Europe offered surgery to carefully selected adults, while psychologists such as John Money built theories of "gender identity" that would later be discredited in their most famous test case.
- The gatekeeping era (late 1970s–2000s). After an influential follow-up study, Johns Hopkins closed its clinic. The remaining services adopted formal Standards of Care with psychiatric assessment, waiting periods and a "real-life test" of living in the opposite sex role before surgery.
- The paediatric and affirmative era (late 1990s–2010s). A Dutch team began giving puberty blockers to screened adolescents. Over the following two decades, assessment requirements were loosened, "gender-affirming" and "informed consent" models spread, and referrals of teenagers, mostly girls, rose many times over.
- The review era (2020 onwards). National evidence reviews in Finland, Sweden, England and the United States found the evidence for youth medical transition weak, and several health systems pulled back.
This page tells that story in order, using primary sources and scholarly histories. Detransitioners and people who transitioned decades ago are among the few who have lived through more than one era, and their accounts are quoted throughout. Some praise the old gatekeeping and some describe it as empty box-ticking. Many describe today's processes as far quicker than anything older patients faced.
Each era was shaped by a small number of clinicians and a thin evidence base. The rules for who could transition have swung from strict psychiatric gatekeeping to self-determination and, in several countries, back towards caution. Long-term outcomes, including how often people detransition, were never systematically tracked through any of these shifts.
The experimental era: Hirschfeld's Berlin institute
Hirschfeld and the Institute for Sexual Science
The German physician Magnus Hirschfeld (1868–1935) was a pioneering sexologist and campaigner for homosexual rights. In his 1910 book Die Transvestiten he described men and women who felt compelled to dress and live as the opposite sex, and coined the term "transvestite" for them. He saw them as one of many natural "sexual intermediaries" (sexuelle Zwischenstufen), a spectrum that for him also included homosexual people and people with intersex conditions.
On 6 July 1919 Hirschfeld opened the Institut für Sexualwissenschaft (Institute for Sexual Science) in Berlin's Tiergarten district. It combined a research library, a public counselling service and a clinic for what he called "sexual transitions", and it campaigned to decriminalise homosexuality (Magnus Hirschfeld Society). The institute also helped some cross-dressing patients obtain police "transvestite passes", which protected them from arrest for wearing women's or men's clothing in public.
The first surgeries
The first known genital operations on people who wished to live as the opposite sex were carried out by doctors connected to the institute. In 1931 the institute physician Felix Abraham published a short paper, "Genitalumwandlungen an zwei männlichen Transvestiten" (genital conversion in two male transvestites), describing the cases of Dora Richter and Toni Ebel. Richter had been castrated in 1922; in 1931 both had their penises removed and artificial vaginas constructed by the surgeons Ludwig Levy-Lenz and Erwin Gohrbandt (Abraham 1931; English translation in the International Journal of Transgenderism, 1998).
The Danish painter Lili Elbe also passed through the institute before a series of operations in Berlin and Dresden in 1930–31. The last was an attempt to transplant a uterus. She died of complications a few months later, in 1931.
These were experiments in the plainest sense. Synthetic sex hormones were barely available, surgical techniques were new, and there was no follow-up beyond case notes. Some detransitioners point out that the goal of these early operations was literal sex change, not the softer language of later decades:
Changing sex has always been the goal. They were trying to transplant ovaries into a man from as soon as these surgeries started (Lili Elbe). —calloutfolly, detrans female
1933: destruction
In May 1933, months after Hitler came to power, Nazi students and stormtroopers looted the institute. Its library was burned in the book burnings on Berlin's Opernplatz on 10 May. Hirschfeld, who was Jewish and gay and was already abroad on a lecture tour, never returned; he died in Nice in 1935. The building was destroyed by bombing in 1943 (Magnus Hirschfeld Society). The loss of the institute's records is one reason so little is known about how its patients fared.
The institute's history is often cited today as evidence that trans people have "always existed" and were targeted by the Nazis. Some detransitioners, particularly lesbian and gay ones, argue that this reading folds Hirschfeld's mostly gay and lesbian clientele into a modern trans category. Others agree that the Berlin era matters, but stress that medical transition itself is recent:
Gender dysphoria has existed for thousands of years. Being able to medically transition and resemble the secondary sex characteristics of the other sex has only been around less than 100 years —oscoxa, MTF currently questioning gender
Christine Jorgensen and Harry Benjamin
Copenhagen, 1952
Medical transition became public knowledge on 1 December 1952, when the New York Daily News ran the front-page headline "Ex-GI Becomes Blonde Beauty". Christine Jorgensen, a former US Army clerk from the Bronx, had been treated in Copenhagen by the endocrinologist Christian Hamburger, the psychiatrist Georg Stürup and the surgeon Erling Dahl-Iversen. She received oestrogen and then castration, which required special permission under Danish law, and later had further genital surgery.
Her doctors published the case in the Journal of the American Medical Association in 1953 under the title "Transvestism: hormonal, psychiatric, and surgical treatment" (Hamburger et al. 1953). After the newspaper coverage, Hamburger received hundreds of letters from people asking for the same treatment. Jorgensen became a celebrity, and her story set the template for the "trapped in the wrong body" narrative that would dominate for decades. The historian Joanne Meyerowitz's How Sex Changed (2002) treats the Jorgensen story as the moment the idea of sex change entered mass culture in the United States (Meyerowitz 2002).
Harry Benjamin and "transsexualism"
The German-born New York endocrinologist Harry Benjamin (1885–1986) had known Hirschfeld in Berlin. From the late 1940s he treated patients referred to him by the sex researcher Alfred Kinsey, and in 1954 he popularised the word "transsexual" to separate people who wanted their bodies changed from "transvestites" who cross-dressed.
His 1966 book The Transsexual Phenomenon argued that psychotherapy could not cure transsexualism and that, for the most severe cases, hormones and surgery were the humane answer (Benjamin 1966). It included his Sex Orientation Scale, which ranked males from Type I (occasional cross-dressers) to Type VI ("true transsexual, high intensity"), for whom surgery was "urgently requested and usually attained; indicated". Almost all of Benjamin's patients were male. The scale linked the "true" transsexual to sexual attraction to men, lifelong distress and a desire for genital surgery. For the long afterlife of this idea, see True trans.
Benjamin's framework had two lasting effects. It legitimised medical transition as treatment rather than mutilation, and it created a checklist of symptoms that patients soon learned to recite.
John Money and the Reimer case
Money's theory of gender
John Money (1921–2006), a New Zealand-born psychologist at Johns Hopkins, studied children born with intersex conditions (differences of sex development). In the mid-1950s he and colleagues argued that a child's sense of being a boy or girl was set mainly by upbringing in the first two to three years, not by chromosomes or hormones. Money popularised the terms "gender role" and later "gender identity" to describe this learned sense of self. On this theory, doctors could assign an infant with ambiguous genitals to either sex, perform surgery early, and expect the child to grow up content as long as the parents raised them consistently. This "optimal gender" policy shaped intersex care for decades (see Intersex and DSDs).
The "John/Joan" case
In 1966 an eight-month-old Canadian boy, David Reimer, lost his penis in a botched circumcision. His parents brought him to Money, who advised raising him as a girl. In 1967, at about 22 months, the child was castrated and given rudimentary female genitals, and was raised as "Brenda". His identical twin brother provided a ready-made control.
Money presented the case as proof of his theory, first in his 1972 book Man & Woman, Boy & Girl and then in a 1975 paper, "Ablatio penis: normal male infant sex-reassigned as a girl" (Money 1975). For two decades it was cited in textbooks as evidence that gender identity is learned.
The reality was different. Reimer never accepted a female identity, was bullied, resisted oestrogen and the planned vaginal surgery, and was put through visits with Money that he later described as traumatic, including sexualised "rehearsals" with his brother. At 14 he was told the truth and returned to living as a boy, later having his breasts removed and a phalloplasty. In 1997 the sexologist Milton Diamond and psychiatrist Keith Sigmundson published a long-term follow-up exposing the case (Diamond & Sigmundson 1997), and journalist John Colapinto told the full story in As Nature Made Him (2000). Reimer's twin brother died of a drug overdose in 2002, and Reimer died by suicide in 2004.
Why the case is contested today
The Reimer case is now used by both sides of the gender debate. Some cite it as proof that an inborn gender identity cannot be overridden. Detransitioners in the database more often read it as a story of medical abuse, and as a warning against trying to make a body fit a theory:
David Reimer is more a cautionary tale than a child transition case
He was damaged, and instead of having to learn to cope with it, the solution was to forcibly change his gender? —IronicJeremyIrons, desisted
I don’t think this proves a disconnected “gender identity” that is seperate from the body. I think this proves that messing with your body can cause deep and profound discomfort even if it doesn’t at first. —portaux, desisted
Money's importance to this history goes beyond Reimer. He helped found the Johns Hopkins Gender Identity Clinic, and his idea that gender identity is a psychological fact separate from sex became a foundation of later gender medicine, even after his own test case failed.
The Johns Hopkins clinic and its closure
Opening, 1966
In November 1966 Johns Hopkins Hospital in Baltimore announced that it had begun performing sex reassignment surgery through a new Gender Identity Clinic. The team included Money, the plastic surgeon Milton Edgerton and psychiatrists. Funding came partly from the Erickson Educational Foundation, set up by Reed Erickson, a wealthy female-to-male transsexual. Hopkins's prestige made the surgery respectable, and within a decade dozens of university programmes had opened, including Stanford (1968), the University of Minnesota and UCLA.
These clinics accepted only a small fraction of applicants. Most wanted patients who matched Benjamin's "true transsexual" profile: long-standing distress, attraction to the same sex, and a believable prospect of "passing" in the new role. Some programmes rejected applicants for being married, for being too masculine or too old, or for being judged unlikely to be attractive in their new sex. Later critics, including some detransitioners, recognise that this was a real problem:
It has to do with how gatekeeping was being abused to keep trans people from ever getting transition or delay it unreasonably. The example was given of someone who was denied transition because they were not going to be attractive enough as a trans woman. That is a really bad reason. So the removal of gatekeeping was in part a reaction to that kind of abuse. —Proper_Imagination, r/detrans commenter
The Meyer–Reter follow-up, 1979
In 1975 the psychiatrist Paul McHugh became head of psychiatry at Hopkins. He was sceptical of surgery and supported a follow-up study by Jon Meyer, director of the clinic, and Donna Reter. Their paper, "Sex reassignment: follow-up", appeared in the Archives of General Psychiatry in August 1979 (Meyer & Reter 1979).
The study followed 50 applicants to the Hopkins clinic, some of whom had surgery and some of whom did not. The researchers scored each person's life before and after on a scale of job, education, marriage and housing stability, and compared those who had been operated on with those who had not. Their abstract notes that "extended evaluation, with a one- to two-year trial period prior to formal consideration of surgery" was already accepted practice. They concluded that surgery gave no objective advantage in social rehabilitation over not having surgery, although most operated patients said they were satisfied.
McHugh later summarised what the follow-up showed in his own words: most patients were content, but "they were no better in their psychological integration or any easier to live with" (McHugh 2004). In 1979 Hopkins stopped performing sex reassignment surgery. The New York Times reported the decision under the headline "Benefits of Transsexual Surgery Disputed as Leading Hospital Halts the Procedure" (Brody 1979). Several other university clinics closed in the following years, and much surgery moved into private practice.
Was the study sound?
The Meyer–Reter study was criticised at the time and since. A 1980 reply by Fleming, Steinman and Bocknek pointed to its small sample, its untested scoring system for "adjustment", and the fact that unoperated patients were not a random control group (Fleming et al. 1980). Critics also note that McHugh had his own strong views. Hopkins resumed gender surgery in 2017.
Its significance is historical rather than statistical. It was one of the first attempts to compare treated and untreated patients on objective outcomes rather than satisfaction alone, and it was followed by no rigorous successor. Decades later, a Swedish national cohort found that people who had sex reassignment between 1973 and 2003 had about three times the overall death rate and about 19 times the suicide rate of the general population, with no untreated comparison group to show whether surgery helped or harmed (Dhejne et al. 2011). The question Meyer and Reter asked, whether surgery improves lives beyond patients' own reports of satisfaction, is still the central question of the field. See Suicide and transition and Transition regret.
The gatekeeping era
Standards of Care and a new diagnosis
In 1979 clinicians around Benjamin founded the Harry Benjamin International Gender Dysphoria Association (HBIGDA), which published the first Standards of Care (SOC) that year. The Standards were minimum criteria for hormones and surgery, designed partly to protect surgeons from lawsuits and partly to protect patients from hasty decisions. In 1980 the American Psychiatric Association's DSM-III added "transsexualism" and "gender identity disorder of childhood" as diagnoses, which meant treatment now required a psychiatric label. See Gender dysphoria for how the diagnosis changed through DSM-IV (1994), DSM-5 (2013) and ICD-11.
Meanwhile, the Stanford psychiatrist Norman Fisk proposed the broader label "gender dysphoria syndrome" in 1974, explicitly to widen (in his word, liberalise) the indications for treatment beyond Benjamin's narrow "true transsexual" (Fisk 1974). The tension between narrowing and widening access runs through every later revision.
The "real-life test"
The defining feature of this era was the real-life test, later renamed the "real-life experience": a period, usually 12 months and sometimes two years, of living full-time in the desired sex role before genital surgery, and in many clinics before hormones. Patients had to work or study as the opposite sex, often change their name, and show the clinic evidence. Early versions of the SOC also required letters from mental health professionals who had known the patient for months.
The rationale was that surgery was irreversible and the test was not. Living as the opposite sex would expose fantasy to reality before anything permanent was done. Some detransitioners say exactly this kind of reality check is what they lacked:
I don't see the harm in it, honestly. It's even better when you live your life that way before you start any rapid changes because then you have time to properly evaluate yourself, see if this is really something that works for you, if it really helps as you thought. —MisterErebos, r/detrans commenter
Many trans people see the same test very differently: as a humiliating ordeal that forced them to live visibly as trans without the physical changes that would let them pass, and as unsafe for those living in hostile places. Some still find echoes of it in today's therapists:
Forcing trans people to come out socially (especially to unaccepting family) as a requirement for medical treatment is absolutely vile.
Pushing for social transition before medical treatments is just the “Real Life Test” shit under a different name. —Lyreii, trans woman (MTF)
The two views disagree on what the test was for. To the trans commenter it was a barrier to necessary care; to detransitioners who support it, it was a chance to find out before it was too late. Both sides agree it was hard.
Learning the script
A recurring theme of the gatekeeping era is that patients learned what clinicians wanted to hear. In her 1987 essay "The Empire Strikes Back", the trans scholar Sandy Stone recounted how Stanford researchers were surprised that applicants fitted Benjamin's profile so neatly, until they realised the applicants had read Benjamin's book too (Stone 1987). Assessment, in other words, could select for knowledge of the script rather than for the condition.
Trans and detrans commenters describe the same practice from opposite ends. Some trans commenters treat lying as a reasonable response to unjust barriers:
It's a decades old tradition by now to lie to therapists as a trans person because they will refuse you your life saving treatment unless you behave exactly the way they want you to. —Alethia_23, trans woman (MTF)
Detransitioners who lied describe it as one way they talked themselves past the safeguards that might have helped them:
The gatekeeping model from the 70's/80's/90's clearly shows people will lie to the medical provider depending on the level of gatekeeping. I personally do advocate for a psychological assessment but that wont stop a majority of them. —0dd3ven, detrans male (socially desisted)
I remember being 16 and going to the gender clinic and I was so scared that they were going to gatekeep me. I was so worried that they would be concerned about the fact that I was literally testifying in court against someone who raped me, had an eating disorder, had a history of depression and suicide attempts, had severe lifelong anxiety and panic attacks but they weren’t concerned about these things at all. —Admirable_Treacle_97, detrans female
This is a real weakness of any assessment-based model, and it is one reason why gatekeeping alone does not prevent regret. It also explains why some detransitioners favour exploratory therapy over a pass/fail assessment (see Gender exploratory therapy).
What older transitioners remember
Accounts from people who transitioned in the 1990s and 2000s are mixed. Some say the old system slowed them down at a time when they would have accepted anything. One detransitioned man who was a teenager in the British system in the 1990s wrote:
When I identified trans I'd have stopped at nothing to gain access to every form of treatment available as soon as it was available. I was a teenager and I knew what I wanted and I wanted it now ...
I can thank 1990's NHS gatekeeping for preventing me from getting too far down the medical pathway over the several years I was under the gender clinic but you can bet I and the other trans teens I associated with through Mermaids didn't lament daily at how slow and "cruel" the offical NHS process was and we all joined in on protests to remove the 2 year social transition "real life test" roadblock they had. —cagedbunny83, detrans male
Others say the gatekeeping was more ritual than scrutiny even then. Someone who transitioned in the United States around 2002 recalls:
With my therapist, I simply told them what I wanted and after a few sessions of talking about it, I received letters for hormones and top surgery. Just having those letters was enough for the endocrinologist and surgeon to proceed. Not a single medical professional questioned or challenged me. —nwtae, r/detrans commenter
A long wait does not always mean careful exploration. A Swedish detransitioner who went through a two-year assessment found that the time was spent mostly waiting:
The only reason the process took so long was the lack of resources, appointments were far between and they were in the nature of just checking in that I hadn’t changed my mind. —christa-paffgen, detrans male
Still, older commenters describe a culture in which transition was seen as a last resort:
Back then it was understood that being trans is fucking hard and transitioning is not something you should do if there's any possible way you could manage to cope in any other fashion. —sambutha, desisted female
Swedish registry data fit the picture of a slow, tightly controlled system. Between 1960 and 2010, applicants for legal and surgical sex change typically waited years, and the system required sterilisation until 2013. About 2.2% of 681 people who completed reassignment later applied to reverse their legal gender, typically around eight years later (Dhejne et al. 2014). Amsterdam records from 1972 to 2015 found regret in under 1% of people who had their gonads removed, but defined regret narrowly and lost track of 36% of patients (Wiepjes et al. 2018). Both figures come from older, more selective systems, and both are often quoted as if they applied today.
The Dutch clinic and puberty blockers
In the 1980s and 1990s a team at Utrecht and later Amsterdam, led by the psychologist Peggy Cohen-Kettenis and the paediatric endocrinologist Henriette Delemarre-van de Waal, began treating adolescents. Their reasoning was that adult transsexuals who transitioned after puberty often struggled to pass, and that pausing puberty in carefully selected teenagers could prevent unwanted changes and buy time.
The first published case appeared in 1998: a single adolescent born female, given a drug that suppresses puberty (a gonadotropin-releasing hormone analogue, or "puberty blocker") to "aid in diagnosis and treatment" (Cohen-Kettenis & van Goozen 1998). By 2006 the team had published a protocol: assessment and diagnosis, blockers from about age 12, cross-sex hormones from 16 and surgery from 18, for adolescents with gender distress since early childhood that worsened at puberty, stable mental health and supportive families (Delemarre-van de Waal & Cohen-Kettenis 2006). The first outcome study followed 70 of these adolescents and became the main evidence base for the approach (de Vries et al. 2011).
This "Dutch protocol" spread internationally: to Boston Children's Hospital in 2007, to the Endocrine Society's guideline in 2009, and to England's Tavistock clinic in an "early intervention" study in 2011. Its design, its outcome studies and their limitations are covered in detail on the Dutch protocol page, and the drugs themselves on Puberty blockers.
Two points matter for this history. First, the Dutch protocol was built for a small, screened, mostly early-onset group. Second, it changed the meaning of the blocker from a diagnostic pause to the first step of transition: in the first Dutch cohort, all 70 adolescents went on to cross-sex hormones. Some older detransitioners remember the period before the protocol spread, when clinics mostly waited to see what happened:
Yes it’s extremely normal, which is why gender clinics used to primarily use “watchful waiting”, to see if the child grew out of it or not. It’s especially common for gay kids. —PeregrinePanic, detrans female
Follow-up studies from the same era, with their own disputed methods, found that most gender-distressed children referred before puberty no longer had gender dysphoria in adolescence (Steensma et al. 2013; Singh et al. 2021). See Desistance.
WPATH Standards of Care, version by version
HBIGDA renamed itself the World Professional Association for Transgender Health (WPATH) in 2006–07. Its Standards of Care have been revised eight times (WPATH). The direction of travel is clear: each revision reduced the requirements for treatment, extended it to younger patients, and widened the population it covered.
| Version | Year | Main features |
|---|---|---|
| SOC 1–3 | 1979, 1980, 1981 | Minimum criteria for adults. Letters from mental health professionals for hormones and surgery; 12 months living full-time in the desired role (real-life test) before genital surgery. |
| SOC 4 | 1990 | Similar requirements; clarified roles of mental health professionals and the sequence hormones → real-life test → surgery. |
| SOC 5 | 1998 | Hormones after either about 3 months of real-life experience or about 3 months of psychotherapy. First provision for puberty suppression in adolescents, with cross-sex hormones possible from 16. |
| SOC 6 | 2001 | Similar to SOC 5; described criteria as "flexible clinical guidelines". |
| SOC 7 | 2011 (published 2012) | Psychotherapy no longer required for hormones; one referral letter for hormones; real-life experience required only before genital surgery (12 months, alongside 12 months of hormones). Endorsed blockers at the start of puberty. Said gender nonconformity should not be judged as inherently pathological (Coleman et al. 2012). |
| SOC 8 | 2022 | Dropped the real-life experience requirement and reduced letters to one for all surgeries. Removed a draft's proposed minimum ages for hormones and surgery. Recommends against making psychotherapy a requirement. Added chapters on non-binary and "eunuch" identities (Coleman et al. 2022). |
SOC 8 was later rated as low quality by independent guideline appraisals (Taylor et al. 2024; Zhang et al. 2026). Court documents also showed that WPATH had restricted publication of the evidence reviews it commissioned from Johns Hopkins, and removed age minimums after pressure from the American Academy of Pediatrics. These episodes are covered on WPATH: the Files, suppressed reviews and scandals.
From gatekeeping to affirmation and informed consent
The affirmative model
In the 2000s and 2010s a new approach emerged, especially in North America. The gender-affirmative model, set out by a group of US clinicians in 2013, holds that gender variations are not disorders, that a child's stated identity should be accepted, and that the clinician's job is to support the child in becoming who they say they are rather than to explore or question that identity (Hidalgo et al. 2013). The American Academy of Pediatrics endorsed this approach in a 2018 policy statement (Rafferty 2018). See American Academy of Pediatrics.
The Endocrine Society's 2009 guideline adopted the Dutch protocol, and its 2017 revision allowed hormones before 16 in some cases, while rating its own evidence for every adolescent recommendation as low or very low quality (Hembree et al. 2009; Hembree et al. 2017). See The Endocrine Society guideline.
The informed consent model
For adults, community health clinics in US cities began offering hormones under an informed consent model: instead of requiring a mental health assessment or letter, a clinician explains the effects and risks, the patient signs a consent form, and a prescription follows, often at the first or second visit. A 2012 survey of such clinics described the model as already established (Deutsch 2012). By the late 2010s, Planned Parenthood had become one of the largest providers of hormones in the United States, and telehealth services began prescribing by video call.
Trans advocates see informed consent as treating trans adults like any other adults making decisions about their own bodies, and as an end to the humiliations of the gatekeeping era:
I personally value informed consent way more than having to go through a process that diagnosed me with a mental illness that doesn’t even exist anymore. —javatimes, trans man (FTM)
Many detransitioners describe the same speed as the problem. Their accounts of how they started hormones are strikingly similar:
I initially got hormones this way. One 30 minute meeting with an NP and a self administered blood pressure test and I had a full dose of hormones for a year. I didn’t even have to talk about being trans. The meeting was just to determine how fast I wanted to transition. —Duchess_Rabbit, detrans female
I picked up my T in a crazed, very obviously unwell state literally right after my first appointment. No mental health screening and barely any family health history screening. Was told multiple times that "most things are reversible." —brokencomputerparts, detrans female
Mine was not informed consent. They literally diagnosed me with gender dysphoria and told me what the treatment was for it. Then I "consented" to the treatment... that they told me was the treatment. —brightescala, detrans female
These accounts are self-selected and cannot show how typical such experiences are. But they are consistent with surveys of detransitioners, most of whom say they did not receive adequate evaluation before transition, and only a minority of whom told their clinicians when they stopped (Littman 2021). See Informed consent in gender medicine.
Older transitioners on the change
Some people who transitioned in earlier decades and later detransitioned or questioned their transition describe the change as a reversal of everything they were taught:
We all also transitioned as adults and had to jump a lot more hoops to transition from than you do today.
Today it’s all the opposite, there are far more trans men, with fewer to no guard rails and far more detransitioning. All this tells me is that there are major problems with the current medical model, and young women/girls who are prone to be uncomfortable with themselves are mistakenly falling into this trans pipeline. —Conscious_Effort_655, questioning own transgender status
It used to frustrate me that I had to wait until adulthood to undergo SRS, but, watching what young people are going through now... Well, I feel awful for all the people who don't have the same opportunity to develop that I did. —Erevi6, desisted female
That was exactly the point of my therapist back in 2013. I am so grateful for making me wait and address my mental health first. —meteorpuppy, desisted female
The referral surge of the 2010s
From about 2010, gender clinics across the Western world saw a sudden rise in referrals, and a change in who was referred.
- Numbers. England's Gender Identity Development Service (GIDS) at the Tavistock received fewer than 100 referrals in 2009/10. By 2021/22 the figure was in the thousands; the Cass Review put it at about 5,000, while noting a strong possibility of double counting in that year. GP records show the share of under-19s in England with a gender dysphoria diagnosis rose more than 50-fold between 2011 and 2021 (Jarvis et al. 2025). In Amsterdam, adult and child assessments rose 20-fold between 1980 and 2015 (Wiepjes et al. 2018).
- Sex ratio. Teenage referrals in Toronto and Amsterdam switched from mostly boys to mostly girls after 2006 (Aitken et al. 2015). At GIDS, adolescent referrals became predominantly female from around 2011 (de Graaf et al. 2018).
- Presentation. Finland's new youth service found that 87% of its first 47 patients were born female, three-quarters had already been in mental health care for other reasons, and most had no recalled gender distress in childhood (Kaltiala-Heino et al. 2015). This was very different from the early-onset group the Dutch protocol was designed for.
Explanations remain contested. Greater acceptance and visibility, social media, peer influence, rising adolescent mental illness and changes in clinical practice have all been proposed; a 2018 parent survey proposed the disputed hypothesis of "rapid-onset gender dysphoria" (Littman 2018). These debates are covered on Demographic shift in trans identification and Rapid-onset gender dysphoria.
Some detransitioners recognise themselves in the graphs:
Especially seeing that chart on the referrals.. that huge boom after around 2011/2012 especially for AFAB is exactly what I expected since that is the exact time I was becoming trans and this shows me more that I really was in that first "wave" of when transitioning became "popular" .. it's crazy. —DEVlLlSH, detrans female
The surge overwhelmed services. Waiting lists at GIDS grew to several years, and clinicians there later said they were under pressure to approve blockers quickly. Detransitioner Keira Bell's 2020 judicial review against the Tavistock brought these concerns to court (Bell v Tavistock; see also The Tavistock GIDS).
The review era
From 2020, a series of national evidence reviews changed course. They used systematic reviews, which search for every relevant study and grade its quality by fixed rules. Their findings are covered in depth on Evidence reviews; this section summarises the sequence.
- Finland (2020). The Council for Choices in Health Care (COHERE) recommended that psychosocial support and treatment of other psychiatric conditions come first for minors, with puberty blockers and hormones considered case by case and with caution, particularly for those whose distress began in adolescence.
- England, NICE (2020–21). Evidence reviews commissioned by NHS England rated the evidence for blockers and cross-sex hormones in adolescents as of very low certainty.
- Sweden (2021–22). The Karolinska University Hospital stopped prescribing blockers and hormones to under-16s outside research in 2021. In 2022 the National Board of Health and Welfare (Socialstyrelsen) concluded that the risks currently outweighed the likely benefits for most adolescents, citing the changed patient population and reports of detransition. See Sweden: Karolinska.
- England, the Cass Review (2022–24). The paediatrician Hilary Cass's independent review found the evidence "remarkably weak", recommended whole-person assessment including screening for autism and mental health conditions, and found that WPATH and other guidelines were poorly developed (Cass 2024; Taylor et al. 2024). GIDS closed in 2024. NHS England stopped routine prescription of blockers outside research, and the UK government made a ban on new private prescriptions indefinite in December 2024 (UK Government 2024).
- Norway (2023). The Norwegian Healthcare Investigation Board called for treatment to be classed as experimental for young people.
- United States (2025). The Department of Health and Human Services published a review of 17 earlier systematic reviews in May 2025, with a revised version naming its authors in November 2025. It rated the evidence for every treatment on mental health outcomes as very weak (HHS 2025). Its independence was disputed: it was ordered by a politically worded executive order, its authors were first unnamed, and several had been paid for legal work on gender medicine. In June 2025 the US Supreme Court upheld Tennessee's ban on medical transition for minors in United States v. Skrmetti (Supreme Court 2025).
Critics of the reviews argue that they applied stricter standards to gender medicine than to other paediatric care, and that low-certainty evidence is common in medicine. Supporters reply that the treatments are permanent, affect fertility and are given to children, which calls for stronger evidence, not weaker. Neither side disputes that the long-term data were never collected; a 2025 systematic review found reported detransition rates ranging from 1% to about 30% depending on definition and follow-up, all on very low quality evidence (Feigerlova 2025).
Many detransitioners see the reviews as a long-overdue recognition of what they experienced. Some note the irony that the countries leading the retreat were those with the strongest reputations for progressive healthcare:
Nordic countries are the most progressive countries in the world. They pioneer many progressive policies, and many other developed countries often eventually adopt their policies. Yes, I do believe regulating children's access to hormones is a progressive policy —split_skunk, detrans male
The reviews concern mainly minors. Adult care, including informed consent clinics, is largely unchanged in most countries. In a sense the field now has two tracks: increasing caution for young people, and continued low-barrier access for adults.
Recurring patterns
Looking across the century, several patterns repeat:
- A small number of influential clinicians. Hirschfeld, Benjamin, Money, the Dutch team and the authors of each SOC shaped practice far more than trials did. Each new model spread before its evidence was tested.
- Changing patients, unchanged protocols. Benjamin's patients were mostly adult males; the Dutch protocol was built for early-onset children; the 2010s surge was mostly adolescent girls with other mental health conditions. Treatments designed for one group were applied to the next.
- Satisfaction versus outcomes. From Meyer and Reter onwards, studies have tended to find that most patients report satisfaction (Meyer & Reter 1979; Wiepjes et al. 2018), while objective measures of wellbeing are less clear (Dhejne et al. 2011). Regret is usually measured narrowly and late.
- Gatekeeping cuts both ways. Strict assessment kept some people from transitions they later valued, and taught others to lie; loose assessment let through people with unaddressed trauma or mental illness. Detransitioners mostly call for better exploration, not simply longer waits.
- No tracking of detransition. None of these eras built systematic follow-up, which is why detransition rates remain unknown. See Detransition.
Timeline
| Year | Event |
|---|---|
| 1910 | Hirschfeld publishes Die Transvestiten. |
| 1919 | Institute for Sexual Science opens in Berlin (6 July). |
| 1922 | Dora Richter castrated, the first known step in a surgical transition. |
| 1930–31 | Genital surgeries on Dora Richter and Toni Ebel; Abraham's report. Lili Elbe's operations; she dies in 1931. |
| 1933 | Nazis loot the institute; its library is burned (May). |
| 1952–53 | Christine Jorgensen's treatment in Copenhagen becomes world news; Hamburger et al. publish in JAMA. |
| 1955 | Money and colleagues set out the theory that gender identity is learned in early childhood. |
| 1966 | Benjamin's The Transsexual Phenomenon. Johns Hopkins announces its Gender Identity Clinic. David Reimer's circumcision injury. |
| 1967 | Reimer surgically reassigned and raised as a girl on Money's advice. |
| 1968 | Stanford opens its gender dysphoria programme. |
| 1974 | Fisk proposes "gender dysphoria syndrome". |
| 1975 | Money's "Ablatio penis" paper presents the Reimer case as a success. McHugh becomes psychiatrist-in-chief at Hopkins. |
| 1979 | Meyer and Reter's follow-up published; Hopkins stops surgery. HBIGDA founded; first Standards of Care. |
| 1980 | DSM-III adds transsexualism and childhood gender identity disorder. |
| 1987 | Sandy Stone's "The Empire Strikes Back". |
| 1989 | UK children's gender service founded (later GIDS at the Tavistock). |
| 1997 | Diamond and Sigmundson expose the Reimer case. |
| 1998 | First Dutch puberty-blocker case report. SOC 5 allows puberty suppression in adolescents. |
| 2006 | Dutch protocol published. HBIGDA becomes WPATH (2006–07). |
| 2007 | Boston Children's Hospital opens the first major US paediatric gender clinic. |
| 2009 | Endocrine Society guideline adopts the Dutch protocol. |
| 2011 | First Dutch blocker outcome study (de Vries et al.). Tavistock early-intervention study begins. SOC 7 drops psychotherapy requirement for hormones. |
| 2012 | Informed consent model described in survey of US clinics. |
| 2013 | DSM-5 replaces gender identity disorder with gender dysphoria. Gender-affirmative model set out. |
| 2015 | Toronto and Amsterdam report reversed sex ratio; Finland reports mostly female, psychiatrically complex referrals. |
| 2017 | Endocrine Society revises guideline. Johns Hopkins resumes gender surgery. |
| 2018 | American Academy of Pediatrics endorses the affirmative model. |
| 2020 | Finland's COHERE prioritises psychosocial care. NICE evidence reviews. Bell v Tavistock High Court ruling. |
| 2021 | Karolinska stops routine blockers and hormones for under-16s. |
| 2022 | Swedish national guidance restricts youth treatment. Cass interim report. WPATH SOC 8 published. ICD-11 takes effect. |
| 2024 | Cass Review final report (April). GIDS closes. UK blocker ban made indefinite (December). |
| 2025 | US HHS evidence review (May; revised November). Supreme Court upholds Tennessee ban in Skrmetti (June). |
Related pages
- Medical transition: evidence, risks and experiences
- Dutch protocol
- Evidence reviews: Cass Review and youth gender medicine
- Puberty blockers
- Informed consent in gender medicine
- WPATH: the Files, suppressed reviews and scandals
- The Endocrine Society guideline
- The Tavistock GIDS
- Sweden: Karolinska and the Trans Train investigations
- Gender dysphoria: meaning and DSM history
- True trans: truscum, gatekeeping and "never really trans"
- Intersex and DSDs
- Demographic shift in trans identification
- Transition regret
- Gender exploratory therapy
References
- Abraham, F. (1931). Genitalumwandlungen an zwei männlichen Transvestiten. Zeitschrift für Sexualwissenschaft und Sexualpolitik 18, 223–226. English translation in International Journal of Transgenderism (1998). Magnus Hirschfeld Society case page.
- Magnus Hirschfeld Society. The Institute for Sexual Science (1919–1933). source.
- Hamburger, C., Stürup, G. K., Dahl-Iversen, E. (1953). Transvestism: hormonal, psychiatric, and surgical treatment. JAMA 152, 391–396. source.
- Benjamin, H. (1966). The Transsexual Phenomenon. Julian Press. source.
- Meyerowitz, J. (2002). How Sex Changed: A History of Transsexuality in the United States. Harvard University Press. source.
- Money, J. (1975). Ablatio penis: normal male infant sex-reassigned as a girl. Archives of Sexual Behavior 4, 65–71. source.
- Diamond, M., Sigmundson, H. K. (1997). Sex reassignment at birth: long-term review and clinical implications. Archives of Pediatrics & Adolescent Medicine 151, 298–304. source.
- Fisk, N. M. (1974). Gender dysphoria syndrome: the conceptualization that liberalizes indications for total gender reorientation. Western Journal of Medicine 120, 386–391. source.
- Meyer, J. K., Reter, D. J. (1979). Sex reassignment: follow-up. Archives of General Psychiatry 36, 1010–1015. source.
- Brody, J. E. (1979). Benefits of transsexual surgery disputed as leading hospital halts the procedure. The New York Times, 2 October. source.
- Fleming, M., Steinman, C., Bocknek, G. (1980). Methodological problems in assessing sex-reassignment surgery: a reply to Meyer and Reter. Archives of Sexual Behavior 9, 451–456. source.
- McHugh, P. (2004). Surgical sex. First Things. source.
- Stone, S. (1987). The Empire Strikes Back: A Posttranssexual Manifesto. source.
- Dhejne, C. et al. (2011). Long-term follow-up of transsexual persons undergoing sex reassignment surgery: cohort study in Sweden. PLOS ONE. study page, source.
- Dhejne, C. et al. (2014). An analysis of all applications for sex reassignment surgery in Sweden, 1960–2010. Archives of Sexual Behavior. study page, source.
- Wiepjes, C. M. et al. (2018). The Amsterdam Cohort of Gender Dysphoria Study (1972–2015). Journal of Sexual Medicine. study page, source.
- Cohen-Kettenis, P. T., van Goozen, S. H. M. (1998). Pubertal delay as an aid in diagnosis and treatment of a transsexual adolescent. European Child & Adolescent Psychiatry 7, 246–248. source.
- Delemarre-van de Waal, H. A., Cohen-Kettenis, P. T. (2006). Clinical management of gender identity disorder in adolescents: a protocol on psychological and paediatric endocrinology aspects. European Journal of Endocrinology 155, S131–S137. source.
- de Vries, A. L. C. et al. (2011). Puberty suppression in adolescents with gender identity disorder: a prospective follow-up study. Journal of Sexual Medicine. study page, source.
- Steensma, T. D. et al. (2013). Factors associated with desistence and persistence of childhood gender dysphoria. JAACAP. study page, source.
- Singh, D., Bradley, S. J., Zucker, K. J. (2021). A follow-up study of boys with gender identity disorder. Frontiers in Psychiatry. study page.
- WPATH. History of the Standards of Care. source.
- Coleman, E. et al. (2012). Standards of Care for the Health of Transsexual, Transgender, and Gender-Nonconforming People, Version 7. International Journal of Transgenderism 13, 165–232. source.
- Coleman, E. et al. (2022). Standards of Care for the Health of Transgender and Gender Diverse People, Version 8. International Journal of Transgender Health. study page, source.
- Taylor, J. et al. (2024). Clinical guidelines for children and adolescents experiencing gender dysphoria or incongruence: a systematic review of guideline quality (part 1). Archives of Disease in Childhood. study page, source.
- Zhang, Y. et al. (2026). Quality of the WPATH Guideline Standards of Care 8: an appraisal using the AGREE II instrument. Archives of Sexual Behavior. study page, source.
- Hidalgo, M. A. et al. (2013). The gender affirmative model: what we know and what we aim to learn. Human Development 56, 285–290. source.
- Rafferty, J. (2018). Ensuring comprehensive care and support for transgender and gender-diverse children and adolescents. Pediatrics 142. source.
- Hembree, W. C. et al. (2009). Endocrine treatment of transsexual persons: an Endocrine Society clinical practice guideline. JCEM 94, 3132–3154. source.
- Hembree, W. C. et al. (2017). Endocrine treatment of gender-dysphoric/gender-incongruent persons: an Endocrine Society clinical practice guideline. JCEM. study page, source.
- Deutsch, M. B. (2012). Use of the informed consent model in the provision of cross-sex hormone therapy: a survey of the practices of selected clinics. International Journal of Transgenderism 13, 140–146. source.
- Littman, L. (2021). Individuals treated for gender dysphoria with medical and/or surgical transition who subsequently detransitioned. Archives of Sexual Behavior. study page.
- Jarvis, S. W. et al. (2025). Epidemiology of gender dysphoria and gender incongruence in children and young people attending primary care practices in England. Archives of Disease in Childhood. study page, source.
- Aitken, M. et al. (2015). Evidence for an altered sex ratio in clinic-referred adolescents with gender dysphoria. Journal of Sexual Medicine. study page, source.
- de Graaf, N. M. et al. (2018). Sex ratio in children and adolescents referred to the Gender Identity Development Service in the UK (2009–2016). Archives of Sexual Behavior 47, 1301–1304. source.
- Kaltiala-Heino, R. et al. (2015). Two years of gender identity service for minors. Child and Adolescent Psychiatry and Mental Health. study page, source.
- Littman, L. (2018). Parent reports of adolescents and young adults perceived to show signs of a rapid onset of gender dysphoria. PLOS ONE. study page, source.
- Cass, H. (2024). Independent review of gender identity services for children and young people: Final report. study page, source.
- UK Government (2024). Ban on puberty blockers to be made indefinite on experts' advice. source.
- US Department of Health and Human Services (2025). Treatment for Pediatric Gender Dysphoria: Review of Evidence and Best Practices. study page, source.
- Supreme Court of the United States (2025). United States v. Skrmetti, No. 23-477. source.
- Feigerlova, E. (2025). Prevalence of detransition in persons seeking gender-affirming hormonal treatments: a systematic review. Journal of Sexual Medicine. study page, source.
Last updated: · 1 view
Suggest an Article or an Improvement
Spotted something missing, unclear or wrong on this page, or have an idea for a related article? Let us know and we'll take a look.
Related pages:
- The Dutch Protocol: The Original Studies and Their Critics
How Dutch clinicians built the puberty-blocker protocol, what the 2011 and 2014 studies found, why critics dispute them, and how practice changed abroad.
- Evidence Reviews: Cass Review and Youth Gender Medicine
What the Cass Review and national evidence reviews in Sweden, Finland, Norway, the US and elsewhere found about youth gender medicine and detransition.
- Cross-Sex Hormones: Effects, Risks and Stopping
How cross-sex hormones are prescribed, what they change, permanent effects, all known risks, weak evidence of benefit, and what detransitioners report.
- Iatrogenic Harm: When Gender Medicine Causes Harm
Iatrogenic harm in gender medicine: harm caused by transition interventions themselves, the mechanisms, the evidence debate and detrans accounts.
- Informed Consent in Gender Medicine: Detrans Accounts
What informed consent means in gender medicine, how detransitioners describe failures of consent, and what research shows about risk disclosure.
- Gender Medicine Scandals and Whistleblowers
Whistleblowers, withheld studies, regulator findings and settlements in youth gender medicine worldwide: what was alleged, what was proven, and outcomes.
- Suicide and Transition: The Narrative vs the Evidence
The "transition or suicide" narrative vs what survey, clinic and register data show: psychiatric confounding, contagion risk, and detrans and trans accounts.
- Transition Surgery: Procedures, Outcomes and Regret
Hub for transition surgeries: what each procedure removes, complication and regret evidence, rising numbers in minors, consent problems and detrans experiences.